Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661056 · ClinicalTrials.gov registry record · Phase 3
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
A Phase 3 study, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT07661056 is a Phase 3 study that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 300 participants.
The verdict
NCT07661056, a Phase 3 study, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Interventions
- DRUG Placebo
- DRUG BHV-1300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-06-26 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07661056
The ClinicalTrials.gov registry entry for NCT07661056 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07661056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07661056 about?
NCT07661056 is a clinical study titled "Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease". The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
What is the current status of trial NCT07661056?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-06-26. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07661056?
The interventions under investigation include: Placebo (DRUG), BHV-1300 (DRUG).
Who is sponsoring clinical trial NCT07661056?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.